August 2025
1. GIRMENIA C, Lazzarotto T, Martino M, Bonifazi F, et al
   Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell and in Solid Organ Transplantation: Updated Recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian Societies.
   Clin Transplant. 2025;39:e70255.
   

   >> Share

   
   July 2025
2. MILLER A, Weeks P, Drake T, Sobhanian M, et al
   Comparison of Short versus Extended Valganciclovir Prophylaxis in Donor-Positive Recipient-Negative Mismatched Heart Transplant Recipients: An Observational Study.
   Clin Transplant. 2025;39:e70223.
   

   >> Share

   
   
3. BANGA N, Kanade R, Kappalayil A, Timofte I, et al
   Long-Term Outcomes Among Lung Transplant Recipients With High-Risk Cytomegalovirus Mismatch Managed With a Multimodality Regimen.
   Clin Transplant. 2025;39:e70219.
   

   >> Share

   
   June 2025
4. COPPOLA JA, Shirley DA, Martin E, Probst V, et al
   Use of Letermovir as Secondary Prophylaxis in Cytomegalovirus Resistant Pediatric Heart Transplant Recipients.
   Clin Transplant. 2025;39:e70187.
   

   >> Share

   
   May 2025
5. KLEIBOEKER HL, Descourouez JL, Saddler CM, Al-Adra D, et al
   De Novo Letermovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients.
   Clin Transplant. 2025;39:e70169.
   

   >> Share

   
   April 2025
6. RAO M, Page RL 2nd, Sartain E
   Twelve-Month Clinical and Cost Outcomes of Removal of Cytomegalovirus Intravenous Immune Globulin From Heart Transplantation Protocol.
   Clin Transplant. 2025;39:e70147.
   

   >> Share

   
   January 2025
7. HELDMAN MR, Messina JA, Schlueter AJ, Lee MJ, et al
   Contemporary Cytomegalovirus (CMV) Infections in Low-Risk CMV Seronegative Recipients of Solid Organ Transplants From CMV Seronegative Donors (D-/R-): Time to Reexamine Donor CMV Serostatus.
   Clin Transplant. 2025;39:e70073.
   

   >> Share

   
   December 2024
8. KLEIBOEKER HL, Prom A, Paplaczyk K, Wang J, et al
   Impact of Letermovir for Cytomegalovirus Primary Prophylaxis on Myelosuppression and Immunosuppression in Lung Transplant Recipients.
   Clin Transplant. 2024;38:e70033.
   

   >> Share

   
   November 2024
9. NON LR, Tan CS, Ince D, Razonable RR, et al
   Survey of Post-Prophylaxis Delayed-Onset Cytomegalovirus Management Strategies Among Transplant Providers.
   Clin Transplant. 2024;38:e70015.
   

   >> Share

   
   October 2024
10. BEECHAR VB, Phadke VK, Pouch SM, Mehta AK, et al
    Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Clin Transplant. 2024;38:e15480.
    

    >> Share

    
    September 2024
11. MACGOWAN GA, Samuel J, McDiarmid A, Gonzalez-Fernandez O, et al
    Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy.
    Clin Transplant. 2024;38:e15419.
    

    >> Share

    
    
12. JORGENSON MR, Meyer E, Leverson GE, Descourouez JL, et al
    Cytomegalovirus Post-Prophylaxis Surveillance in High-Risk Kidney and Liver Recipients Prevents CMV End-Organ Disease and Ganciclovir-Resistance.
    Clin Transplant. 2024;38:e15453.
    

    >> Share

    
    June 2024
13. GAN GG, Iyadorai T, Sulaiman NY, Hussein N, et al
    Clinical and Economic Impact of CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation: Perspectives from a Middle-Income Nation.
    Clin Transplant. 2024;38:e15375.
    

    >> Share

    
    May 2024
14. SALTIEL G, Faure E, Assaf A, Chopin MC, et al
    Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
    Clin Transplant. 2024;38:e15327.
    

    >> Share

    
    April 2024
15. RAMPERSAD C, Kong W, Wiebe C, Balshaw R, et al
    Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein-Barr virus, cytomegalovirus, and BK polyomavirus post-kidney transplant: A quality assurance initiative.
    Clin Transplant. 2024;38:e15292.
    

    >> Share

    
    
16. CHIU CY, Mahmood M, Razonable RR, Beam E, et al
    Discordance in serology for cytomegalovirus, Epstein-Barr virus and toxoplasma among thoracic organ donors.
    Clin Transplant. 2024;38:e15301.
    

    >> Share

    
    
17. CUI J, Zhou Y, Zhao K, Li X, et al
    Application of CMV-IVIg as prophylaxis against cytomegalovirus reactivation in allogeneic hematopoietic stem cell transplantation patients.
    Clin Transplant. 2024;38:e15300.
    

    >> Share

    
    March 2024
18. ROMINE MM, Leeser DB, Kennamer K, Nguyen C, et al
    Early outcomes associated with de novo once-daily extended-release versus twice-daily immediate-release tacrolimus in a predominantly African American kidney transplant population: A single-center observational study.
    Clin Transplant. 2024;38:e15268.
    

    >> Share

    
    
19. ALAM AH, Van Zyl J, Shakoor HI, Farsakh D, et al
    The impact of active cytomegalovirus infection on donor-derived cell-free DNA testing in heart transplant recipients.
    Clin Transplant. 2024;38:e15287.
    

    >> Share

    
    December 2023
20. ZAIS IE, Sirotti A, Iesari S, Campioli E, et al
    Human cytomegalovirus-related gastrointestinal disease after kidney transplantation: A systematic review.
    Clin Transplant. 2023 Dec 8:e15218. doi: 10.1111/ctr.15218.
    

    >> Share

    
    November 2023
21. SINGH P, Von Stein L, McGowan M, Nolan A, et al
    Comparison of outcomes in vaccinated versus unvaccinated COVID-19 kidney transplant recipients, a single center retrospective study-Is the taboo justified?
    Clin Transplant. 2023 Nov 7:e15187. doi: 10.1111/ctr.15187.
    

    >> Share

    
    
22. ZHOU X, Zhang S, Fan J, Zhu X, et al
    Risk factors for BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Clin Transplant. 2023;37:e15121.
    

    >> Share

    
    October 2023
23. DIOVERTI MV, Bhaimia E, Yetmar ZA, Melendez DP, et al
    Clinical utility of a cytomegalovirus-specific T cell assay in assessing the risk of post-prophylaxis cytomegalovirus infection and post-treatment relapse.
    Clin Transplant. 2023 Oct 8:e15143. doi: 10.1111/ctr.15143.
    

    >> Share

    
    September 2023
24. JORGENSON MR, Descourouez JL, Saddler CM, Smith JA, et al
    Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
    Clin Transplant. 2023 Sep 27:e15142. doi: 10.1111/ctr.15142.
    

    >> Share

    
    August 2023
25. SERMET K, Goeminne C, Hantz S, Assaf A, et al
    Reliability of QuantiFERON(R)-CMV in predicting CMV recurrence in heart transplant recipients: A single-center retrospective study.
    Clin Transplant. 2023 Aug 29:e15109. doi: 10.1111/ctr.15109.
    

    >> Share

    
    July 2023
26. LERMAN JB, Green CL, Molina MR, Maharaj V, et al
    Multicenter study of universal prophylaxis versus pre-emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation.
    Clin Transplant. 2023 Jul 1:e15065. doi: 10.1111/ctr.15065.
    

    >> Share

    
    May 2023
27. KREISER ML, Dupuis R, Szempruch KR, Chargualaf LM, et al
    Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high-risk abdominal transplant recipients.
    Clin Transplant. 2023 May 31:e15041. doi: 10.1111/ctr.15041.
    

    >> Share

    
    March 2023
28. GARDINER BJ, Bailey JP, Percival MA, Morgan BA, et al
    Incidence and severity of cytomegalovirus infection in seropositive heart transplant recipients.
    Clin Transplant. 2023 Mar 29:e14982. doi: 10.1111/ctr.14982.
    

    >> Share

    
    
29. ZONA E, Jorgenson M, Dolma S, Santos A, et al
    Discordance in cytomegalovirus viremia in kidney recipients from the same donor is associated with the worst outcomes.
    Clin Transplant. 2023 Mar 26:e14979. doi: 10.1111/ctr.14979.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share